Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

1.270 +0.190 (+17.59%)
Streaming Delayed Price Updated: 10:19 AM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Via ACCESS Newswire
News headline image
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire
News headline image
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
News headline image
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
News headline image
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Via ACCESS Newswire
News headline image
Dermata Opens a New Chapter with the Release of Tome Skincare
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Via ACCESS Newswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.